Related Experiment Video

Updated: Feb 3, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K

Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems

Anna Garmpi1, Nikolaos Garmpis, Christos Damaskos

  • 1Internal Medicine Department, "Laiko" General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology
|October 26, 2018
PubMed

Insights

Histone deacetylase inhibitors (HDACIs) show promise in cancer treatment by inducing cell death and modulating immune responses. Approved HDACIs treat certain lymphomas and myeloma, with others in clinical trials for various malignancies.

Area of Science:

  • Epigenetics
  • Molecular Biology
  • Cancer Research

Background:

  • Histone acetylation is crucial for epigenetic gene regulation.
  • Histone deacetylases (HDACs) and histone acetyltransferases maintain this balance.
  • Histone deacetylase inhibitors (HDACIs) disrupt this balance, impacting cancer cell behavior.

Purpose of the Study:

  • To explore the anticancer mechanisms of HDACIs.
  • To review the therapeutic potential of HDACIs in various malignancies.
  • To summarize the current clinical applications and ongoing trials of HDACIs.

Main Methods:

  • Review of scientific literature on HDACIs and their anticancer effects.
  • Analysis of approved HDACIs and their indications.
  • Summary of ongoing clinical trials involving HDACIs for hematological and solid tumors.

Main Results:

  • HDACIs induce cancer cell cycle arrest, differentiation, and apoptosis.
  • HDACIs can inhibit angiogenesis and modulate the immune system.
  • Vorinostat, romidepsin, belinostat, and panobinostat are approved for specific hematological cancers.
  • Numerous HDACIs are under investigation in clinical trials for diverse cancers.

Conclusions:

  • HDACIs represent a promising class of drugs for cancer therapy.
  • While current results are encouraging, larger clinical studies are necessary to fully establish their efficacy and safety across various malignancies.

More Related Videos

Single-Step Enrichment of a TAP-Tagged Histone Deacetylase of the Filamentous Fungus Aspergillus nidulans for Enzymatic Activity Assay09:07

Single-Step Enrichment of a TAP-Tagged Histone Deacetylase of the Filamentous Fungus Aspergillus nidulans for Enzymatic Activity Assay

Published on: May 1, 2019

7.3K
Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

47.4K

Related Concept Videos

Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
16.1K
Histone Modification02:32

Histone Modification

4.5K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Expected Value01:15

Expected Value

The expected value is known as the "long-term" average or mean. This means that over the long term of experimenting over and over, you would expect this average. The expected average is represented by the symbol μ. It is calculated as follows:
7.8K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.1K
Determination of Expected Frequency01:08

Determination of Expected Frequency

Suppose one wants to test independence between the two variables of a contingency table. The values in the table constitute the observed frequencies of the dataset. But how does one determine the expected frequency of the dataset? One of the important assumptions is that the two variables are independent, which means the variables do not influence each other. For independent variables, the statistical probability of any event involving both variables is calculated by multiplying the individual...
2.6K